Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vaneltix Pharma, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for VNX-001](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cystitis, Interstitial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IC/BPS | P2 |
Not yet recruiting |
Cystitis, Interstitial |
2025-06-01 |
|
VNX001-111 | P2 |
Recruiting |
Cystitis, Interstitial |
2024-05-22 |